A clinical trial is in progress to evaluate the effects of efavirenz (EFV), a CYP46A1 activator, on people with mild cognitive impairment due to Alzheimer’s disease (ClinicalTrials.gov: NCT03706885). The gene discussed is CYP46A1; the disease is Alzheimer disease.